Drug Trial Radar · NCT03630081
Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Last checked: Nov 19, 2026Latest source record: Jul 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,004
Planned (sponsor's estimate)
Start
Jan 2024
Primary completion
Jan 2026
Study completion Feb 2026
Sponsor
- Lead sponsor
- WockhardtIndustry
- Sponsor type
- Industry
- First posted
- Aug 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of FEP-TAZ vs. meropenem in the treatment of hospitalized adults with cUTI or AP.
Conditions
- Complicated Urinary Tract Infection
- Acute Pyelonephritis
Interventions
WCK 4282 (FEP-TAZ) 4 gDrug
WCK 4282 (FEP-TAZ) 4 g \[2 g FEP and 2 g TAZ\] IV q8h, infused over 90 min
MeropenemDrug
1 g IV q8h, infused over 45 min
ciprofloxacin 500 mg Optional Oral SwitchDrug
ciprofloxacin 500 mg PO q12h
Infusion of normal salineOther
Infusion of normal saline over 45 min
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with overall success at Day 5Time frame: Day 5
- Percentage of subjects with overall success at Test-of-CureTime frame: Test Of Cure Visit (Day 17 ± 2 days)
- Percentage of subjects with Treatment-Emergent Adverse Events (TEAE)Time frame: Day 1 to the end of study Late Follow-Up visit (LFU) (26 ± 2 days)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.